Supplement Registration Indonesia: Jamu, Quasi, or SK? The Classification Guide That Prevents Costly Delays

Every year, foreign brands stall their Indonesia market entry not because their product fails safety testing, but because they file under the wrong BPOM category. Supplement registration Indonesia is not a single path; it is a regulated fork in the road, and the direction taken at the start determines everything that follows.

Under Indonesia’s BPOM framework, three distinct categories are often grouped together: health supplements (suplemen kesehatan or SK), traditional medicine (obat tradisional or OT), そして quasi medicine (obat kuasi). Each carries different rules, different permitted claims, and a different documentation burden. Misreading these boundaries is the leading cause of rejections across all supplement registration Indonesia applications in the functional health product space.

Why Category Confusion Makes Supplement Registration Indonesia Harder in 2026

Indonesia’s health and wellness market is expanding at a pace that outstrips regulatory literacy among incoming brands. According to Grand View Research, Indonesia’s dietary supplements market was valued at USD 2.94 billion in 2025, projected to reach USD 6.43 billion by 2033 at a CAGR of 10.3%. The herbal medicine sector adds another layer, with the market valued at USD 13.7 billion in 2024 and forecast to grow at 7.1% annually through 2033.

This growth is fuelled by products sitting squarely between categories: adaptogen blends, nutraceuticals, functional beverages, and topical wellness products. When a brand cannot cleanly identify which category fits before pursuing supplement registration Indonesia, BPOM typically requires a full resubmission. That restart costs months and, in many cases, significant laboratory and consultancy expenditure.

The Regulatory Framework Behind Supplement Registration Indonesia

BPOM, the Badan Pengawas Obat dan Makanan, is Indonesia’s national drug and food control agency, operating under Presidential Decree No. 80/2017. In late 2025, BPOM received formal WHO Listed Authority recognition, signalling increasing alignment with international standards.

In 2025, BPOM also launched a Regulatory Development Program under Decision No. 278/2025 to revise and streamline regulations across pharmaceuticals, supplements, and cosmetics. The program signals a broader push toward ICH and ASEAN guideline alignment. For supplement registration Indonesia applications, the most directly relevant instruments are listed below.

Key regulations in force as of 2026:

• PerBPOM No. 10 of 2024 (effective 1 January 2025): Governs labelling obligations across natural medicines, quasi medicines, and health supplements
• BPOM Regulation No. 6 of 2025: Introduces stability testing requirements for many supplement categories
• BPOM Decree No. 70 of 2025: Revises ingredient classifications for health supplements
• BPOM Regulation No. 34 of 2022: Supervises advertising of traditional drugs, quasi drugs, and health supplements
• BPOM Regulation No. 23 of 2025: Updates drug registration evaluation timelines and labelling requirements
• Law No. 17 of 2023 on Health: Overarching statutory framework for all BPOM-regulated categories

重要： A January 2026 BPOM draft regulation also proposes mandatory disclosures on ingredient origins and alcohol content for all regulated product categories, including supplements and traditional medicines. Public consultation closed 12 January 2026; final implementation is pending.

How BPOM Defines Health Supplements in Supplement Registration Indonesia

あ health supplement, or suplemen kesehatan (SK), is a product designed to supplement the diet by providing nutrients or bioactive substances. Think vitamins, minerals, amino acids, fatty acids, and concentrated herbal extracts in standardized dosage forms. The BPOM review process for health supplements takes between three and six months from the date of a complete submission, and once granted, a registration number (NIE) is valid for five years.

The defining principle is that health supplements must not make therapeutic claims. A product cannot state it will treat, cure, or prevent a specific disease. It can describe nutritional support, general wellness, or normal physiological functions. Any claim that moves beyond this boundary immediately shifts the product into either the traditional medicine or pharmaceutical category.

Key characteristics of health supplements under BPOM:

• Registered under the POM SD code
• Includes vitamins, minerals, amino acids, herbs in concentrated form
• No therapeutic claims permitted on label or in advertising
• Subject to BPOM Regulation No. 34 of 2022 on advertising supervision
• Must begin distribution within one year of receiving the NIE
• Import realization reports must be submitted to BPOM every six months post-registration

プロのヒント: If a product label says “supports immune function,” that is a supplement claim. If it says “treats colds,” that requires clinical backing and a different BPOM category entirely.

関連している： Health Supplement Registration in Indonesia: A Step-by-Step Guide for Foreign Manufacturers

How BPOM Defines Traditional Medicine (Jamu, OHT, and Fitofarmaka)

Traditional medicine, or obat tradisional (OT), covers products derived from natural sources with a history of traditional use in Indonesian health culture. BPOM divides traditional medicine into three tiers based on scientific evidence level. For brands pursuing jamu registration Indonesia, the entry point is the base Jamu tier, which relies on empirical evidence accumulated over generations.

OHT (Obat Herbal Terstandar) requires preclinical safety and efficacy data, standardized raw materials, and Good Agricultural and Collection Practices compliance. Fitofarmaka represents the highest tier, requiring full clinical trials and manufacturing standards equivalent to modern pharmaceutical products. Understanding which tier fits a product is as important as the supplement registration Indonesia category decision itself.

Jamu (POM TR)

Jamu is the foundational tier of traditional medicine in Indonesia. Efficacy is proven through empirical, intergenerational use rather than formal trials. Products can take the form of dried simplicia, powders, liquids, capsules, or tablets. BPOM requires compliance with basic safety standards and CPOTB manufacturing practices.

In December 2023, jamu wellness culture received formal UNESCO Intangible Cultural Heritage recognition. Foreign brands seeking jamu registration Indonesia should note that providing documentation of a product’s traditional formulation history is typically the most challenging part of the dossier preparation.

Obat Herbal Terstandar / OHT (POM HT)

OHT sits between jamu and fitofarmaka. Products must demonstrate safety and efficacy through preclinical testing, and raw materials must be standardized. Brands like Tolak Angin and Diapet are registered at this tier. OHT is commercially the most viable path for herbal products with scientifically documented ingredient profiles.

For imported products, all preclinical documentation must be translated and verified against Indonesian standards. BPOM scrutinizes raw material sourcing for botanical ingredients, requiring certificates of analysis covering heavy metals, pesticide residues, and microbial contaminants. An EU CE mark or US FDA approval does not replace Indonesian requirements.

Fitofarmaka (FF)

Fitofarmaka is Indonesia’s highest natural medicine category. As of the latest BPOM data, only 23 products hold fitofarmaka registration in Indonesia. It requires full clinical evidence, validated standardized extracts, and documentation equivalent to a modern pharmaceutical drug submission.

Stimuno, an immune-support product, is one of the most cited fitofarmaka examples. For most foreign investors entering the nutraceutical Indonesia BPOM category space, fitofarmaka is not the practical starting point. It suits brands with completed clinical trial data and dedicated regulatory budgets.

Explore:

• Indonesia Product Certification 2026: SNI, BPOM, and Halal Requirements Explained
• Indonesia’s Health Supplement Gold Rush: Why Now Is the Time for Strategic Market Entry

The Category Most Brands Overlook: Quasi Medicine (Obat Kuasi)

Quasi medicine, or obat kuasi, is the category that consistently confuses foreign brands and regulatory newcomers alike. It sits between a traditional herbal product and a conventional drug. Under PerBPOM No. 10 of 2024, quasi drugs contain active ingredients with mild therapeutic effects but do not fully meet the criteria of a registered pharmaceutical drug.

In practical terms, quasi medicines include antiseptics, disinfectants, topical wound treatments, mouthwashes with mild antimicrobial activity, and certain preventive health products. The OT supplement classification BPOM assigns to quasi drugs is POM QD, and advertising is governed by BPOM Regulation No. 34 of 2022, the same instrument that applies to traditional medicines and health supplements.

Products that commonly fall under quasi medicine:

• Antiseptic mouthwashes and gargles
• Topical wound sprays and antiseptic liquids
• Medicated plasters with mild analgesic effect
• Preventive nasal sprays not classified as pharmaceuticals
• Certain hair loss treatments with mild scalp-active ingredients

プロのヒント: Many brands assume a product with an antiseptic or disinfectant function registers as a health supplement. It does not. BPOM places those products in the quasi medicine category, which carries a different dossier structure and distinct label requirements.

Side-by-Side: Traditional Medicine, Quasi Medicine, and Health Supplements

The table below summarizes the key regulatory differences across all four classification types. This is the reference point that foreign brands should use before deciding which pathway to pursue for supplement registration Indonesia.

Criteria	Jamu (OT)	OHT / Fitofarmaka	Quasi Medicine	Health Supplement
Regulatory basis	Empirical / traditional use	Preclinical (OHT) or clinical trials (Fitofarmaka)	Mild therapeutic effect; not classified as a full drug	Nutrient supplementation; no therapeutic claims
Typical ingredients	Herbs, roots, plant extracts (e.g., turmeric, ginger)	Standardized botanical extracts with documented bioactivity	Antiseptics, disinfectants, preventive topical agents	Vitamins, minerals, amino acids, concentrated herbal extracts
Health claims permitted?	Limited empirical claims only	Broader claims with supporting evidence	Mild preventive or maintenance claims	No therapeutic claims; nutritional support only
BPOM registration code	POM TR / POM HT / FF	POM HT (OHT) / FF (Fitofarmaka)	POM QD	POM SD
GMP standard required	CPOTB	CPOTB + higher documentation	CPOTB / pharmaceutical GMP depending on form	CPOTB or pharmaceutical GMP
NIE registration valid for	5 years	5 years	5 years	5 years
Common examples	Turmeric-tamarind blend, beras kencur tonic	Tolak Angin (OHT), Stimuno (Fitofarmaka)	Antiseptic mouthwash, topical wound spray	Vitamin C tablet, fish oil capsule, iron supplement

The Critical Difference: What Claims a Product Can Legally Make

Label claims are where classification confusion becomes commercially dangerous. Filing under the wrong category with an impermissible claim does not just trigger a rejection. In serious cases, it can expose the importer or distributor to product recall and potential license suspension under PerBPOM No. 10 of 2024. Misleading or inaccurate information can even result in criminal proceedings under BPOM authority.

The following is a practical summary of what each category permits on product packaging and in advertising:

Health supplement claims (permitted):

• Provides [nutrient] to support normal [body function]
• Contributes to daily nutritional intake
• Supports general health and wellbeing

Traditional medicine claims (permitted, with appropriate tier evidence):

• Helps maintain stamina (Jamu level)
• Clinically proven to support digestive health (OHT or Fitofarmaka level)
• Empirically used to relieve mild fatigue (Jamu level)

Quasi medicine claims (permitted):

• Antiseptic protection against skin bacteria
• Mild analgesic relief for topical application
• Preventive oral hygiene maintenance

Claims never permitted across any category:

• Treats, cures, or prevents a specific disease (pharmaceutical territory)
• Clinically proven to reverse a medical condition (unless fitofarmaka level with clinical trials)
• Replaces or acts as a substitute for prescription medication

プロのヒント: A turmeric-and-ginger capsule marketed for “immune support” registers comfortably as a health supplement. The same product described as “proven to prevent respiratory infection” requires OHT or fitofarmaka documentation. The ingredient does not change; the claim does.

Decision Guide: Which Category Fits Your Product for Supplement Registration Indonesia?

Before approaching BPOM, a brand should work through a structured classification assessment. The following guided questions narrow the field and help avoid the most common pitfalls in supplement registration Indonesia.

Step 1: What is the primary ingredient type?

• Vitamins, minerals, amino acids, or concentrated herbal extracts with no traditional formulation history = Health Supplement
• Traditional botanical ingredients with documented empirical or preclinical efficacy = Traditional Medicine (Jamu or OHT tier)
• Active ingredient with mild therapeutic or antiseptic function = Quasi Medicine

Step 2: What claims does the brand intend to make?

• Nutritional support only, no disease references = Health Supplement
• Empirical wellness benefits from natural ingredients = Jamu
• Scientifically validated health function = OHT or Fitofarmaka
• Mild therapeutic or hygiene claims = Quasi Medicine

Step 3: What level of clinical documentation does the brand hold?

• No trials: Jamu or Health Supplement route
• Preclinical data only: OHT route
• Full clinical trial data: Fitofarmaka route

Step 4: What is the dosage form and delivery method?

• Oral capsule, tablet, or powder with nutritional intent = Health Supplement or Jamu/OHT
• Topical application with antiseptic or mild therapeutic function = Quasi Medicine
• Drink, tonic, or herbal blend based on traditional recipe = Jamu

Real-World Classification Examples for Supplement Registration Indonesia

The following examples show how common product types would be classified by BPOM under current rules. They cover the most searched categories in the nutraceutical Indonesia BPOM space and illustrate why product classification must be confirmed before initiating supplement registration Indonesia.

Vitamin C tablet (1,000 mg):

Health supplement (POM SD). No traditional formulation history, no disease treatment claims. Nutrient supplementation in a concentrated oral dosage form.

Turmeric and black pepper capsule with immunity claim:

Traditional medicine, Jamu or OHT tier depending on evidence level. Botanical ingredients with traditional use history. If only empirical evidence is available, this registers as Jamu. If preclinical standardization data exists, OHT is the appropriate path.

Fish oil softgel (Omega-3, EPA/DHA):

Health supplement (POM SD). Positioned as nutritional support for cardiovascular and brain health within permitted claim boundaries. No therapeutic claims.

Antiseptic mouthwash with chlorhexidine:

Quasi medicine (POM QD). Contains an active ingredient with mild antimicrobial therapeutic function. Not a food-grade supplement and not a traditional herbal blend.

Ginseng extract capsule marketed for stamina:

Traditional medicine (Jamu or OHT tier). Ginseng holds documented traditional use in Indonesian health practice. The stamina claim qualifies as an empirical wellness claim under the OT framework.

Probiotic capsule marketed for digestive comfort:

Health supplement (POM SD). Probiotics in capsule form with digestive support claims, provided no therapeutic disease-treatment language appears on the label.

Adaptogen blend (ashwagandha, lion’s mane) marketed as a stress support formula:

Classification depends on intended claims and whether each ingredient appears on BPOM’s Positive List. If claims stay within nutritional support boundaries, health supplement applies. If traditional botanical evidence is cited, the Jamu or OHT pathway may be more appropriate. BPOM’s list of restricted plant species must be reviewed before formulation is finalized.

What Happens When a Brand Gets the Classification Wrong

Classification errors are the most consistent source of timeline risk in the supplement registration Indonesia process. BPOM evaluators are trained to identify claim-category mismatches during dossier review. When a mismatch is detected, the outcome is not a simple correction. According to regulatory compliance specialists, misclassification triggers a full dossier rejection requiring resubmission from the beginning.

The practical consequences extend well beyond a paperwork reset. Laboratory tests conducted under the wrong category assumption cannot be transferred. Stability test data prepared for a health supplement dossier, for example, does not satisfy OHT documentation requirements. Each category has its own analytical method requirements and testing scope.

Documented consequences of wrong-category filing:

• Full dossier rejection and mandatory resubmission with an entirely new submission reference number
• Laboratory testing costs written off, as results are non-transferable between categories
• Potential reformulation if the product does not meet standards for the correct category
• Timeline delays of three to twelve months depending on reclassification complexity
• For products already on the market, post-surveillance detection can trigger recall and fines under PerBPOM No. 10 of 2024
• Repeated or serious non-compliance can escalate to suspension of the distributor’s import or distribution license
• In the most serious cases, BPOM has authority to initiate criminal proceedings for misleading product information.

重要： Selling a health supplement in Indonesia without a valid NIE is a regulatory violation. Non-compliant products may be seized, recalled, or subject to enforcement action regardless of whether they were sold online or in physical retail. E-commerce platforms in Indonesia increasingly require a valid BPOM number before listing any health product.

The 2026 regulatory environment makes misclassification risk higher, not lower. BPOM’s active update cycle, including the stability testing requirements under Regulation No. 6 of 2025 and revised ingredient classifications under Decree No. 70 of 2025, means that even products with completed supplement registration Indonesia under earlier rules may face additional compliance requirements at the next renewal cycle.

プロのヒント: Brands entering the functional health supplement Indonesia segment should conduct a pre-classification assessment before initiating any laboratory testing. Testing conducted under the wrong category assumption is non-transferable and cannot be reused.

Getting Classification Right: Where Expert Advisory Support Matters

For companies unfamiliar with Indonesia’s regulatory environment, the classification decision is rarely straightforward. Many functional products, especially those in the adaptogens, nutraceuticals, and botanical extracts space, have ingredient and claim profiles that straddle two or more of the categories described above.

Business Hub Asia works with foreign companies at precisely this pre-registration stage, helping clients map the most defensible classification pathway ahead of supplement registration Indonesia, reviewing ingredient lists and intended label claims, and preparing documentation structures aligned with BPOM’s current requirements. Early classification clarity reduces the risk of rejection at the dossier evaluation stage and shortens the overall time to market authorization.

Updated Indonesian Regulations Shaping Supplement Registration Indonesia in 2026

Anyone involved in supplement registration Indonesia or traditional medicine import Indonesia should maintain awareness of the current regulatory landscape. The table below summarizes the key instruments in active force or development as of 2026.

• PerBPOM No. 10 of 2024 (effective 1 Jan 2025): Labelling obligations for natural medicines, quasi medicines, and health supplements. Mandates disclosure of product name, dosage form, business operator identity, composition, benefit claims, and usage instructions.
• BPOM Regulation No. 6 of 2025: Introduces stability testing requirements for health supplements, making the submission process more technically demanding.
• BPOM Decree No. 70 of 2025: Revises the ingredient classification list for health supplements, affecting which botanicals and nutrients are pre-approved for use.
• BPOM Regulation No. 34 of 2022: Governs advertising of traditional drugs, quasi drugs, and health supplements across all media.
• BPOM Regulation No. 23 of 2025 (effective August 2025): Updates drug registration evaluation timelines and labelling requirements, with implications for product categories bordering pharmaceutical classification.
• January 2026 Draft Regulation: Proposes mandatory ingredient origin and alcohol content disclosures across all regulated categories. Final implementation timeline pending.
• Law No. 17 of 2023 on Health: The overarching legislation providing the statutory framework for all BPOM product categories.

Summary: Get the Category Right Before Anything Else

Indonesia’s health product market is one of the most dynamic in Southeast Asia, and its regulatory system is active, technically demanding, and increasingly internationally aligned. The line between a health supplement, a traditional herbal medicine, and a quasi drug is not intuitive, and the consequences of a misclassification go well beyond a paperwork correction.

For any brand considering supplement registration Indonesia, the most important step is not filing a dossier. It is confirming, with regulatory certainty, that the product belongs in the right category from the start. That single decision shapes the permitted claim language, the laboratory testing scope, the documentation structure, and ultimately the speed and cost of reaching Indonesian consumers.